BRAIN AG purchases the outstanding 24.7% minority stake of WeissBioTech GmbH
B.R.A.I.N. Biotechnology Research and Information Network AG announces today the purchase of the outstanding 24.7% minority stake of WeissBioTech GmbH from founder Hans de Bie. Terms and conditions of the deal will not be publicly disclosed.
In 2014 BRAIN AG made a strategic investment into WeissBioTech to gain access to the growing and profitable enzyme market. Since then, BRAIN AG and WeissBioTech have worked closely together to discover, develop and sell innovative enzyme products and solutions for customers worldwide.
In 2018, BRAIN AG made another key strategic move through its acquisition of Biocatalysts Ltd. in Cardiff, UK, an enzyme company with strong fermentation technology and enzyme R&D, serving specialty niche markets. Together with BRAIN's extensive enzyme technology skills, the WeissBioTech and Biocatalysts capabilities will form a solid platform for strong growth in the specialty enzymes business.
Adriaan Moelker, CEO BRAIN AG, states: “We are continuously working to build and optimize the group structure as announced during our capital increase in June, 2020. The full acquisition and integration of WeissBioTech GmbH gives us important flexibility to optimize our production network and capture synergies within the group. I would particularly like to thank founder Hans de Bie for his significant contribution to the development of the company - and Lukas Linnig at BRAIN who made this agreement come to fruition. Ultimately, all our stakeholders will benefit from this transaction.“
About BRAIN
BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.
BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).
Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.
BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.
For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.
Disclaimer
This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.